P2X purinoceptor 7–NLR family pyrin domain containing 3 axis (P2X7R-NLRP3 axis)

The P2X7 receptor–NLRP3 axis is a critical pro-inflammatory signaling pathway that links extracellular danger signals to the innate immune response [1, 3]. The P2X7 receptor (P2X7R) is an ATP-gated non-selective cation channel primarily expressed on immune cells like macrophages and microglia [1, 2]. Upon activation by high concentrations of extracellular ATP—often released during tissue damage or stress—P2X7R facilitates a rapid efflux of potassium ions (K+) [8, 10]. This drop in intracellular potassium is a primary trigger for the assembly and activation of the NLRP3 inflammasome, a multi-protein complex consisting of NLRP3, the adapter protein ASC, and pro-caspase-1 [3, 7]. Activation of the axis leads to the maturation and secretion of potent pro-inflammatory cytokines, specifically interleukin-1beta (IL-1beta) and interleukin-18 (IL-18) [3, 10]. Furthermore, this signaling cascade can induce pyroptosis, a form of programmed inflammatory cell death characterized by cell swelling and membrane rupture [3, 10]. This axis is heavily implicated in the pathogenesis of various chronic inflammatory and neurodegenerative diseases, including Alzheimer's disease, rheumatoid arthritis, and metabolic disorders [1, 4, 5]. Consequently, pharmacological inhibition of either P2X7R or NLRP3 is a major area of drug development aimed at treating conditions driven by dysregulated inflammation [3, 6]. Therapeutic strategies targeting this axis include small molecule antagonists of P2X7R and direct inhibitors of the NLRP3 protein [3, 7]. Monitoring biomarkers such as IL-1beta levels and caspase-1 activity is essential for evaluating the efficacy of these interventions in clinical settings [4, 11].

Other names

P2X7R-NLRP3 inflammasome pathwayATP-P2X7-NLRP3 axisP2X7-NLRP3-IL-1beta pathwayP2X7-NLRP3 signaling axis

Extracellular ATP activates the P2X7 receptor, causing potassium efflux, which triggers the assembly of the NLRP3 inflammasome, leading to caspase-1 activation and the release of IL-1beta and IL-18.